Short Interest in Integra LifeSciences Holdings Co. (NASDAQ:IART) Rises By 16.1%

Integra LifeSciences Holdings Co. (NASDAQ:IART) was the target of a significant growth in short interest in October. As of October 15th, there was short interest totalling 5,110,000 shares, a growth of 16.1% from the September 30th total of 4,400,000 shares. Currently, 7.9% of the shares of the company are short sold. Based on an average trading volume of 1,110,000 shares, the short-interest ratio is presently 4.6 days.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of IART. Capital Research Global Investors raised its position in Integra LifeSciences by 37.7% in the first quarter. Capital Research Global Investors now owns 5,918,981 shares of the life sciences company’s stock valued at $209,828,000 after purchasing an additional 1,621,655 shares during the last quarter. Cooke & Bieler LP raised its holdings in Integra LifeSciences by 12.4% in the 2nd quarter. Cooke & Bieler LP now owns 3,514,281 shares of the life sciences company’s stock valued at $102,406,000 after buying an additional 388,710 shares during the last quarter. Champlain Investment Partners LLC boosted its position in Integra LifeSciences by 10.3% during the 1st quarter. Champlain Investment Partners LLC now owns 2,687,972 shares of the life sciences company’s stock worth $95,289,000 after buying an additional 252,015 shares during the period. Dimensional Fund Advisors LP grew its holdings in Integra LifeSciences by 0.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,785,009 shares of the life sciences company’s stock worth $52,014,000 after acquiring an additional 12,766 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. increased its position in Integra LifeSciences by 64.6% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 855,352 shares of the life sciences company’s stock valued at $24,925,000 after acquiring an additional 335,557 shares during the period. 84.78% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. BTIG Research raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. Morgan Stanley increased their price target on Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a research report on Monday, July 15th. Citigroup dropped their price objective on Integra LifeSciences from $20.00 to $16.00 and set a “sell” rating for the company in a report on Tuesday, October 1st. Truist Financial reduced their target price on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a report on Monday, October 14th. Finally, Bank of America dropped their price target on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research note on Monday, October 7th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Integra LifeSciences has an average rating of “Hold” and a consensus target price of $26.50.

Integra LifeSciences Stock Down 0.1 %

IART stock opened at $19.48 on Thursday. The firm has a 50-day moving average price of $18.69 and a 200-day moving average price of $24.70. Integra LifeSciences has a 12 month low of $16.81 and a 12 month high of $45.42. The company has a current ratio of 3.39, a quick ratio of 2.10 and a debt-to-equity ratio of 1.17. The stock has a market capitalization of $1.51 billion, a P/E ratio of 67.17, a price-to-earnings-growth ratio of 0.65 and a beta of 1.09.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Monday, July 29th. The life sciences company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.62 by $0.01. The business had revenue of $418.20 million during the quarter, compared to the consensus estimate of $413.07 million. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The firm’s revenue was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.71 EPS. As a group, equities research analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.